Levomilnacipran Completed Phase 3 Trials for Depression / Major Depressive Disorder (MDD) Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02431806Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder
NCT01085812Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
NCT02720198Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD
NCT00969150Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
NCT00969709Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
NCT01034267Safety Study of F2695 SR in Major Depressive Disorder
NCT01034462Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
NCT01377194Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder